NBIX - Neurocrine Biosciences, Inc.
59.03 0.00 (0.00%)
After hours: 4:24PM EDT
| Previous Close | 58.96 |
| Open | 58.59 |
| Bid | 52.90 x 100 |
| Ask | 63.40 x 100 |
| Day's Range | 57.71 - 60.56 |
| 52 Week Range | 37.35 - 63.77 |
| Volume | 1,032,193 |
| Avg. Volume | 827,584 |
| Market Cap | 5.21B |
| Beta | 1.52 |
| PE Ratio (TTM) | -23.40 |
| EPS (TTM) | -2.52 |
| Earnings Date | Oct 31, 2017 - Nov 6, 2017 |
| Forward Dividend & Yield | 0.00 (0.00%) |
| Ex-Dividend Date | 1995-12-29 |
| 1y Target Est | 74.42 |
Markit•2 days agoSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
- Market Realist•4 days ago
How Is Neurocrine Biosciences Positioned Now?
In the first half of 2017, Neurocine Biosciences (NBIX) generated revenues of $6.3 billion and reported expenses on the cost of product sales of $61.0 million.
Markit•7 days agoSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
Markit•10 days agoSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
- MarketWatch•15 days ago
UPDATED: Neurocrine stock up 3% on higher-dose approval of tardive dyskinesia drug
Neurocrine Biosciences Inc. shares rose 3% in premarket trade Thursday after the company said the Food and Drug Administration has approved a higher, 80 mg dose of its tardive dyskinesia drug. The 80 mg ...
- PR Newswire•15 days ago
Neurocrine Announces FDA Approval of 80 mg INGREZZA® (valbenazine) Capsules for the Treatment of Adults with Tardive Dyskinesia (TD)
SAN DIEGO, Oct. 5, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that the U.S. Food and Drug Administration (FDA) has approved an 80 mg INGREZZA® (valbenazine) capsule strength to be used for the treatment of adults with tardive dyskinesia (TD). INGREZZA, a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, which was approved by the FDA April 11, 2017, is the first FDA-approved product indicated for the treatment of adults with TD. "INGREZZA continues to be the TD treatment of choice," said Kevin C. Gorman, Chief Executive Officer of Neurocrine Biosciences.
Markit•25 days agoSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
Markit•28 days agoSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
- ACCESSWIRE•28 days ago
Today's Research Reports on Stocks to Watch: Neurocrine Biosciences and Biocryst Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / September 22, 2017 / Shares of Neurocrine saw a pop on Thursday after a Baird analyst reiterated an "outperform" rating on the stock. Shares of BioCryst also saw gains ...
- Investor's Business Daily•29 days ago
Stocks To Watch: Neurocrine Biosciences Sees Relative Strength Rating Jump To 91
Neurocrine Biosciences shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
Markit•last monthSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
- PR Newswire•last month
Neurocrine Announces Data on the Real-World Patient Impact of TD from the RE-KINECT Study to be Presented at the 2017 Annual Psych Congress
SAN DIEGO, Sept. 15, 2017 /PRNewswire/ -- Neurocrine Biosciences Inc. (NBIX) announced today upcoming poster presentations at the 2017 Annual Psych Congress featuring data from the RE-KINECT study outlining the real-world presence and impact of tardive dyskinesia (TD) on the lives of both patients and caregivers. "This year's Psych Congress serves as an excellent opportunity to dive deeper into the patient impact of TD, including demographics and healthcare utilization. The RE-KINECT study provides valuable insight into the complexities and needs of these patients and how INGREZZA can address the movements that may disrupt patient lives," said Chris O'Brien, M.D., Chief Medical Officer of Neurocrine.
Markit•last monthSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
- PR Newswire•last month
Neurocrine Biosciences to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
Live Audio Webcast Will be on September 11, 2017 SAN DIEGO , Sept. 6, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman , CEO of Neurocrine Biosciences, ...
- PR Newswire•last month
AbbVie Submits New Drug Application to U.S. FDA for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain
- In clinical studies, elagolix demonstrated superiority compared to placebo in reducing three types of endometriosis-associated pain - daily menstrual pelvic pain, non-menstrual pelvic pain and painful ...
- Market Realist•last month
Behind Bioverativ’s Analyst Recommendations This September
Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a "hold."
Markit•2 months agoSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
- PR Newswire•2 months ago
Neurocrine Biosciences to Present at the Baird 2017 Global Healthcare Conference
Live Audio Webcast Will be on September 6, 2017 SAN DIEGO , Aug. 30, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman , CEO of Neurocrine Biosciences, ...
- Investor's Business Daily•2 months ago
Stocks To Watch: Neurocrine Biosciences Sees Relative Strength Rating Jump To 82
Neurocrine Biosciences shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 82.
Markit•2 months agoSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: Portola Pharmaceuticals Inc. and Neurocrine Biosciences, Inc.
NEW YORK, NY / ACCESSWIRE / August 25, 2017 / U.S. markets closed in the red Thursday as investors await comments on monetary policy from the annual meeting of central bankers in Jackson Hole, Wyoming. ...
Markit•2 months agoSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
Markit•2 months agoSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
Markit•2 months agoSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of NBIX earnings conference call or presentation 9-May-17 9:00pm GMT
Q1 2017 Neurocrine Biosciences Inc Earnings Call
